AI Stock Analysis - Johnson & Johnson (JNJ)
Analysis generated November 25, 2025.
Johnson & Johnson (J&J) is a multinational corporation with interests in pharmaceuticals, medical devices, and consumer health products. Founded in 1886, J&J has a robust global presence, providing a diverse range of healthcare solutions. The company's operations are segmented into three main divisions: Pharmaceutical, Medical Devices, and Consumer Health.
Stock Alerts - Johnson & Johnson (JNJ)
 |
Johnson & Johnson | January 16 Julie Johnson (member of U.S. congress) is selling shares |
|
Johnson & Johnson | January 5 Job postings are down by 22.6% in the last couple of days. |
|
Johnson & Johnson | January 5 Lloyd Doggett (member of U.S. congress) is buying shares |
|
Johnson & Johnson | January 3 Job postings are down by 17.1% in the last couple of days. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Johnson & Johnson
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.
| Price | $224.44 |
| Target Price | Sign up |
| Volume | 8,150,000 |
| Market Cap | $530B |
| Year Range | $147.77 - $224.44 |
| Dividend Yield | 2.35% |
| PE Ratio | 19.96 |
| Analyst Rating | 43% buy |
| Industry | Drug Manufacturers |
In the news
 |
Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and SmileJanuary 27 - Jnj.com |
 |
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on ItJanuary 25 - Yahoo |
Johnson & Johnson price target raised to $250 from $222 at TD CowenJanuary 23 - Yahoo Entertainment |
|
|
How Johnson & Johnson’s 2025 Beat and 2026 Sales Guidance Could Shape JNJ Investors’ OutlookJanuary 23 - Yahoo |
|
ETFs to Buy Post JNJ's Q4 Earnings Surprise & Bullish Cash Flow ViewJanuary 23 - Yahoo |
|
Johnson & Johnson Quietly Triggers a Trend Following Buy SignalJanuary 23 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '25 | 24.6B | 7.97B | 16.6B | 5.12B | 0 | 2.460 |
| Q3 '25 | 24B | 7.3B | 16.7B | 5.15B | 9.29B | 2.800 |
| Q2 '25 | 23.7B | 7.63B | 16.1B | 5.54B | 8.74B | 2.770 |
| Q1 '25 | 21.9B | 7.36B | 14.5B | 11B | 15.6B | 2.770 |
| Q4 '24 | 22.5B | 7.13B | 15.4B | 3.43B | 5.92B | 2.040 |
Insider Transactions View All
| MORIKIS JOHN G filed to buy 1,849 shares at $206.2. December 1 '25 |
| REED JOHN C filed to sell 10,658 shares at $192.7. October 20 '25 |
| Taubert Jennifer L filed to sell 178,013 shares at $177.8. September 5 '25 |
| Duato Joaquin filed to sell 275,967 shares at $179.2. August 25 '25 |
| Wolk Joseph J filed to sell 14,000 shares at $176.9. August 18 '25 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Eli Lilly and CompanyLLY |
$1039.51 2.2% | 62 |
 |
PfizerPFE |
$26.5 2.4% | 51 |
 |
AstrazenecaAZN |
$95.6 1.5% | 49 |
 |
AbbVieABBV |
$223.93 1.4% | 53 |
 |
TherapeuticsMDTXMD |
$2.42 12.6% | 51 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Julie Johnson |
Jan 16, 26 | Sell | $1K - $15K |
| Lloyd Doggett |
Jan 5, 26 | Buy | $1K - $15K |
| Thomas H. Kean |
Dec 19, 25 | Sell | $15K - $50K |
Read more about Johnson & Johnson (JNJ) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
FAQ - Johnson & Johnson
The Market Cap of Johnson & Johnson is $530B.
As of today, Johnson & Johnson's PE (Price to Earnings) ratio is 19.96.
Currently, the price of one share of Johnson & Johnson stock is $224.44.
The JNJ stock price chart above provides a comprehensive visual representation of Johnson & Johnson's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Johnson & Johnson shares. Our platform offers an up-to-date JNJ stock price chart, along with technical data analysis and alternative data insights.
Yes, Johnson & Johnson (JNJ) offers dividends to its shareholders, with a dividend yield of 2.35%. This dividend yield represents Johnson & Johnson's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Johnson & Johnson in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
Some of the similar stocks of Johnson & Johnson are Eli Lilly and Company, Pfizer, Astrazeneca, AbbVie, and TherapeuticsMD.
